Anti-Proteases and Alpha-1 Antitrypsin Augmentation Therapy

References

1. 1.↵
   1. Laurell CB,
   2. Eriksson S

   . The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. 1963. COPD 2013;10(Suppl 1):3–8.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Snider GL,
   2. Lucey EC,
   3. Stone PJ

   . Animal models of emphysema. Am Rev Respir Dis 1986;133(1):149–169.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Curiel DT,
   2. Chytil A,
   3. Courtney M,
   4. Crystal RG

   . Serum alpha 1-antitrypsin deficiency associated with the common S-type (Glu264—-Val) mutation results from intracellular degradation of alpha 1-antitrypsin prior to secretion. J Biol Chem 1989;264(18):10477–10486.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Campos MA,
   2. Wanner A,
   3. Zhang G,
   4. Sandhaus RA

   . Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest 2005;128(3):1179–1186.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, Global initiative for chronic obstructive lung disease. Updated 2017. www.goldcopd.org.
6. 6.↵
   American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168(7):818–900.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Brantly ML,
   2. Paul LD,
   3. Miller BH,
   4. Falk RT,
   5. Wu M,
   6. Crystal RG

   . Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis 1988;138(2):327–336.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.
   1. Tobin MJ,
   2. Cook PJ,
   3. Hutchison DC

   . Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z: a survey by the British Thoracic Association. Br J Dis Chest 1983;77(1):14–27.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Janus ED,
   2. Phillips NT,
   3. Carrell RW

   . Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985;1(8421):152–154.

   OpenUrlPubMedWeb of Science
10. 10.↵
    1. Bernspång E,
    2. Sveger T,
    3. Piitulainen E

    . Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. Respir Med 2007;101(9):1971–1976.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Parr DG,
    2. Guest PG,
    3. Reynolds JH,
    4. Dowson LJ,
    5. Stockley RA

    . Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007;176(12):1215–1221.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Bergin DA,
    2. Reeves EP,
    3. Meleady P,
    4. Henry M,
    5. McElvaney OJ,
    6. Carroll TP,
    7. et al

    . Alpha-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Investig 2010;120(12):4236–4250.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Mahadeva R,
    2. Atkinson C,
    3. Li Z,
    4. Stewart S,
    5. Janciauskiene S,
    6. Kelley DG,
    7. et al

    . Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005;166(2):377–386.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Hubbard RC,
    2. Fells G,
    3. Gadek J,
    4. Pacholok S,
    5. Humes J,
    6. Crystal RG

    . Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency: spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Investig 1991;88(3):891–897.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Dirksen A,
    2. Dijkman JH,
    3. Madsen F,
    4. Stoel B,
    5. Hutchison DC,
    6. Ulrik CS,
    7. et al

    . A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160(5 Pt 1):1468–1472.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    Food and Drug Administration. Proceedings of Meeting of Blood and Plasma Advisory Committee. Rockville, Maryland: Food and Drug Administration; 1998.
17. 17.↵
    1. Dawkins PA,
    2. Dowson LJ,
    3. Guest PJ,
    4. Stockley RA

    . Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003;58(12):1020–1026.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Gadek JE,
    2. Klein HG,
    3. Holland PV,
    4. Crystal RG

    . Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Investig 1981;68(5):1158–1165.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Wewers MD,
    2. Casolaro MA,
    3. Sellers SE,
    4. Swayze SC,
    5. McPhaul KM,
    6. Wittes JT,
    7. Crystal RG

    . Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316(17):1055–1062.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Seersholm N,
    2. Kok-Jensen A

    . Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 1995;151(2 Pt 1):369–373.

    OpenUrlPubMedWeb of Science
21. 21.↵
    1. Molloy K,
    2. Hersh CP,
    3. Morris VB,
    4. Carroll TP,
    5. O'Connor CA,
    6. Lasky-Su JA,
    7. et al

    . Clarification of the risk of chronic obstructive pulmonary disease in alpha1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014;189(4):419–427.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Chapman KR,
    2. Burdon JG,
    3. Piitulainen E,
    4. Sandhaus RA,
    5. Seersholm N,
    6. Stocks JM,
    7. et al

    . Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015;386(9991):360–368.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. McElvaney NG,
    2. Burdon J,
    3. Holmes M,
    4. Glanville A,
    5. Wark PA,
    6. Thompson PJ,
    7. et al

    . Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med 2017;5(1):51–60.

    OpenUrl
24. 24.↵
    The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998;158(1):49–59.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Silverman EK,
    2. Sandhaus RA

    . Clinical practice: alpha1-antitrypsin deficiency. N Engl J Med 2009;360(26):2749–2757.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Campos MA,
    2. Kueppers F,
    3. Stocks JM,
    4. Strange C,
    5. Chen J,
    6. Griffin R,
    7. et al

    . Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). COPD 2013;10(6):687–695.

    OpenUrlCrossRef
27. 27.↵
    1. Wencker M,
    2. Banik N,
    3. Buhl R,
    4. Seidel R,
    5. Konietzko N

    . Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998;11(2):428–433.

    OpenUrlAbstract
28. 28.↵
    1. Meyer FJ,
    2. Wencker M,
    3. Teschler H,
    4. Steveling H,
    5. Sennekamp J,
    6. Costabel U,
    7. Konietzko N

    . Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Eur Respir J 1998;12(4):996–997.

    OpenUrlAbstract
29. 29.↵
    1. Ziomek CA

    . Commercialization of proteins produced in the mammary gland. Theriogenology 1998;49(1):139–144.

    OpenUrlCrossRefPubMed
30. 30.
    1. Wright G,
    2. Carver A,
    3. Cottom D,
    4. Reeves D,
    5. Scott A,
    6. Simons P,
    7. et al

    . High level expression of active human alpha-1-antitrypsin in the milk of transgenic sheep. Bio/technology 1991;9(9):830–834.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Casolaro MA,
    2. Fells G,
    3. Wewers M,
    4. Pierce JE,
    5. Ogushi F,
    6. Hubbard R,
    7. et al

    . Augmentation of lung antineutrophil elastase capacity with recombinant human alpha-1-antitrypsin. J Appl Physiol 1987;63(5):2015–2023.

    OpenUrlPubMed
32. 32.↵
    1. Hubbard RC,
    2. McElvaney NG,
    3. Sellers SE,
    4. Healy JT,
    5. Czerski DB,
    6. Crystal RG

    . Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J Clin Investig 1989;84(4):1349–1354.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Monk R,
    2. Graves M,
    3. Williams P,
    4. Strange C

    . Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. COPD 2013;10(4):411–415.

    OpenUrl
34. 34.↵
    1. Sclar DA,
    2. Evans MA,
    3. Robison LM,
    4. Skaer TL

    . Alpha1-proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to alpha1-antitrypsin deficiency: number and costs of years of life gained. Clin Drug Investig 2012;32(5):353–360.

    OpenUrlPubMed
35. 35.↵
    1. Gildea TR,
    2. Shermock KM,
    3. Singer ME,
    4. Stoller JK

    . Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003;167(10):1387–1392.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    1. Hubbard RC,
    2. Sellers S,
    3. Czerski D,
    4. Stephens L,
    5. Crystal RG

    . Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988;260(9):1259–1264.

    OpenUrlCrossRefPubMedWeb of Science
37. 37.
    1. Barker AF,
    2. Iwata-Morgan I,
    3. Oveson L,
    4. Roussel R

    . Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997;112(3):607–613.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Cammarata SK,
    2. Stone CL,
    3. Carey JL,
    4. Eichenhorn MS

    . Failure to achieve adequate serum levels with monthly replacement therapy in alpha 1-antitrypsin deficiency. Chest 1994;106(2):651–652.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Zamora NP,
    2. Pla RV,
    3. Del Rio PG,
    4. Margaleff RJ,
    5. Frias FR,
    6. Ronsano JB

    . Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy. Ann Pharmacother 2008;42(5):640–646.

    OpenUrlCrossRefPubMed
40. 40.↵
    1. Soy D,
    2. de la Roza C,
    3. Lara B,
    4. Esquinas C,
    5. Torres A,
    6. Miravitlles M

    . Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax 2006;61(12):1059–1064.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Sandhaus RA,
    2. Turino G,
    3. Stocks J,
    4. Strange C,
    5. Trapnell BC,
    6. Silverman EK,
    7. et al

    . Alpha1-antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest 2008;134(4):831–834.

    OpenUrlCrossRefPubMedWeb of Science
42. 42.↵
    1. Turino GM,
    2. Barker AF,
    3. Brantly ML,
    4. Cohen AB,
    5. Connelly RP,
    6. Crystal RG,
    7. et al

    . Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996;154(6 Pt 1):1718–1725.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.↵
    1. Trulock EP

    . Lung transplantation for alpha 1-antitrypsin deficiency emphysema. Chest 1996;110(6 Suppl):284S–294S.

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Chan ED,
    2. Kaminska AM,
    3. Gill W,
    4. Chmura K,
    5. Feldman NE,
    6. Bai X,
    7. et al

    . Alpha-1-antitrypsin (alpha-1 antitrypsin) anomalies are associated with lung disease due to rapidly growing mycobacteria and alpha-1 antitrypsin inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis 2007;39(8):690–696.

    OpenUrlCrossRefPubMedWeb of Science